Yupelri and Rashes - a phase IV clinical study of FDA data

Summary:

Rashes is reported as a side effect among people who take Yupelri (revefenacin), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Brovana, and have Immunodeficiency common variable.

The phase IV clinical study analyzes which people have Rashes when taking Yupelri. It is created by eHealthMe based on reports of 505 people who have side effects when taking Yupelri from the FDA, and is updated regularly.

What is Yupelri?

Yupelri has active ingredients of revefenacin. eHealthMe is studying from 506 Yupelri users. Check the latest studies of Yupelri.

What is Rashes?

Rashes (redness) is found to be associated with 3,714 drugs and 6,214 conditions by eHealthMe. Check the latest studies of Rashes.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Jul, 12, 2026

505 people reported to have side effects when taking Yupelri.
Among them, 23 people (4.55%) have Rashes.

Among these 23 people:

How long have people been on Yupelri when they have Rashes? *

What is the gender of people who have Rashes when taking Yupelri? *

female: 69.57 %
male: 30.43 %

What is the age of people who have Rashes when taking Yupelri? *

What are other drugs people take besides Yupelri? *

What are other side effects people have besides Rashes? *

Dyspnea (difficult or laboured breathing): 10 people, 43.48%
Abdominal Pain: 6 people, 26.09%
Infusion Site Erythema (reddening of the skin at infusion site): 6 people, 26.09%
Cellulitis (infection under the skin): 6 people, 26.09%
Infusion Site Pruritus (severe itching at infusion site): 6 people, 26.09%
Back Pain: 5 people, 21.74%
Sinusitis (inflammation of sinus): 5 people, 21.74%
Nausea (feeling of having an urge to vomit): 4 people, 17.39%
Localised Infection (infection at the single location): 4 people, 17.39%
Limb Injury: 4 people, 17.39%

What are the existing conditions these people have? *

Immunodeficiency Common Variable: 7 people, 30.43%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 4 people, 17.39%
Asthma: 3 people, 13.04%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 2 people, 8.70%
Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 1 person, 4.35%
Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it): 1 person, 4.35%

* Approximation only. Some reports may have incomplete information.

Do you take Yupelri and have Rashes?

- Check whether Rashes is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Yupelri:

Yupelri (506 reports)

Rashes treatments and more:

Rashes (702,909 reports)

Browse all side effects of Yupelri:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Rashes:

Rashes (3,714 drugs)

Browse all the conditions that are associated with Rashes:

Rashes (6,214 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on revefenacin (the active ingredients of Yupelri) and Yupelri (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.